Of the four prostaglandin (PG) E receptor subtypes (EP1-EP4), EP2 and EP4 have been proposed to mediate the anabolic action of PGE 2 on bone formation and some comparative evaluation studies of EPs on bone formation have been done, but their relative impacts on bone formation including downstream MAPK pathways remain unresolved. To dissect this issue, we systematically assessed the roles of EPs in the rat calvaria (RC) cell culture model by using four selective EP agonist (EPA)s. Consistent with relative expression levels of the respective receptors, multiple phenotypic traits of bone formation in vitro, including proliferation of nodule-associated cells, osteoblast marker expression and mineralized nodule formation were upregulated not only by PGE 2 but equally by EP2A and EP4A, but not by EP1A and EP3A. EP2A and EP4A were effective when cells were treated chronically or pulse-treated during nascent nodule formation. EP2A and EP4A equally stimulated the endogenous PGE 2 production, while EP2A caused a greater increase in cAMP production and c-fos gene expression compared to EP4A. EP2A and EP4A activated predominantly p38 MAPK and ERK respectively, while c-Jun N-terminal kinase (JNK) was equally activated by both agonists. SB203580 (p38 MAPK inhibitor) blocked the PGE 2 effect on mineralized nodule formation, while U0126 (ERK inhibitor) and dicumarol (JNK inhibitor) were less effective. PGE 2 -dependent phosphorylation of the MAPKs was affected not only by protein kinase (PK)A and PKC inhibitors but also by adenylate cyclase and PKC activators.
Introduction
It is well established that prostaglandin (PG) E 2 increases bone mass and strength when administered systemically or locally to the skeleton by acting on the growth and differentiation of osteoblastic cells [1] . Over the last decade, the molecular mechanisms underlying PGE 2 actions on bone formation are becoming apparent; for example, PGE 2 alters expression of molecules which are crucial for osteoblast development and function, including runt-related transcription factor 2 (Runx2) [2] and transforming growth factor (TGF)-β type III receptor [3] . However, how the signaling output from PGE receptor (EP) subtypes contributes to bone formation is not fully resolved. Four specific G protein-coupled EP subtypes (EP1-EP4) have been identified and are known to be differentially expressed across tissue types [4] . It is also known that EP1 couples to Ca 2+ mobilization, and EP2 and EP4 activate, whereas EP3 inhibits, adenylate cyclase. Given such a multiplicity of biological responses, it is not surprising that PGE 2 is involved in a number of physiological and pathophysiological events [5] .
After each of the four EP receptor subtypes-lacking mice were generated, which receptor plays a role in bone metabolism has been investigated. A study using EP1 and EP2 receptor knockout mice showed that EP2 receptor has a major influence on the biomechanical properties of bone rather than EP1 receptor [6] , and the studies using EP4 knockout mice [7] and cell culture derived from those [8] demonstrated that the lack of EP4 receptor had no influence of PGE 2 -induced bone formation. Recently, new agonists with high affinity and selectivity for each EP receptor subtype (EP1A-EP4A) have been described [5, 9] . A local injection of CP-533,536, an EP2-selective agonist, stimulates bone formation in canines [10] and rats [11] fracture and/or normal models, suggesting that EP2plays a role in PGE 2 -dependent bone formation. On the other hand, the studies conducted daily injection of ONO-4891 [12] and CP-734,432 [13] , both EP4-selective agonists, in rats show that EP4
agonists have a potential of the prevention and treatment of osteoporosis. PGE 2 is involved in activation of mitogen-activated protein kinase (MAPK)s [14] , and which MAPKs are linked to EP receptor subtypes has been extensively investigated in non-skeletal cells, such as colorectal tumors [15] . For example, EP4 but not EP2 signaling leads to phosphorylation of the ERKs through a phosphatidylinositol 3-kinase (PI3K)-dependent pathway in HEK 293 cells ectopically expressing EP2 and EP4 [16] .
What about bone? Limited information is available on the question of how EPs activate
MAPKs for bone formation. PGE 2 stimulates fibronectin through the EP1/phospholipase C/protein kinase (PK)C/c-Src signaling pathway in rat osteoblasts [17] . The PKC pathway is also involved in PGE 2 -induced cell proliferation via ERK in the MC3T3-E1 osteoblastic cell line [14] .
The diverse effects of PGE 2 on bone in vivo and osteoblastic cells in vitro suggest that unambiguous understanding of the molecular mediators of the anabolic action of PGE 2 on bone formation is still lacking. In addition, in spite of the marked effects of PGE 2 on bone formation, its receptor subtype-dependent multiple actions cause severe side effects including diarrhea, lethargy, and flushing [18] , making it an unacceptable therapeutic option in humans. Thus, simple but systematic approaches that reflect in vivo phenomena are still required to address the molecular pathways by which EP receptor subtypes act on osteoblast development. To this end, we have compared the effects of EP1A-EP4A in well-established rat bone formation models in vitro and found that MAPK pathways active predominately in nascent nodule-forming cells, which may contribute to PGE 2 actions on bone formation in an EP2 and EP4 receptor subtype-specific dependent manner.
Materials and Methods

Reagents
Selective EP agonists (EP1A, ONO-DI-004; EP2A, ONO-AEI-259; EP3A, ONO-AE-248; EP4A, ONO-AE1-437) were gifts from Ono Pharmaceutical Co. (Osaka, Japan) [19] . Both recombinant human bone morphogenetic protein 2 (rBMP2) and Noggin (rNoggin), an antagonist of BMPs, were purchased from PeproTech (Rocky Hill, NJ). H89, a PKA inhibitor, and Go6850, a PKC inhibitor, were obtained from D. Western Therapeutics Institute (Nagoya, Japan) and Calbiochem (Darmstadt, Germany), respectively. Forskolin (an adenylate cyclase activator), phorbol 12-myristate 13-acetate (PMA, an activator of PKC), PGE 2 , MAPK inhibitors (for p38 MAPK, SB203580; for c-Jun N-terminal kinase (JNK), dicumarol; for ERK, U0126) and all other chemicals, unless otherwise specified, were purchased from Sigma-Aldrich (St Louis, MO). Stock solutions were prepared in dimethylslufoxide and diluted with medium (1,000 times or more) before use.
Animals
Animal use and procedures were approved by the Committee of Research Facilities for Laboratory Animal Science, Hiroshima University and the University of Toronto Animal Care Committee. Rats were euthanized by cervical dislocation or deep anesthesia.
Tissue and cell preparation and immunohistochemistry
Twenty-one-day-old rat fetal (embryonic day 21 (E21)) and newborn Wistar rat (day 8) parietal bones were fixed in 4% paraformaldehyde and embedded in paraffin using standard protocols. Cells grown on coverslips at day 7 (nascent nodule formation stage, see below)
were fixed and stored in acetone at −20 °C until use. Coronal sections (4.5 μm in thickness) or cultured cells were treated with antibodies against EP2, EP4 or Runx2 (1:50, Santa Cruz Biotechnology, Santa Cruz, CA) at 4 °C overnight, followed by incubation with Cy Grove, PA) for 1 h. Each incubation step was followed by two washes with PBS (5 min each). As negative control, normal goat or rabbit IgG (Vector Lab, Burlingame, CA) or vehicle alone replaced primary antibodies. Neighboring sections were stained with hematoxylin and eosin.
Cell cultures
Rat calvaria (RC) cells were routinely obtained from fetuses (Wistar, E21) as described [20] . Briefly, calvariae were minced and digested with collagenase (type I) for 10, 20, 30, 50 and 70 min at 37 °C. Cells retrieved from the last four of five digestion fractions were separately grown in αMEM containing 10% fetal calf serum (FCS, Biological Industries, Beit Haemek, Israel; Cansera, Etobicoke, Canada) and antibiotics. After 24 h, cells were pooled and grown in multi-well plates or 35-mm dishes (0.3×10 4 cells/cm 2 ) in the same medium supplemented additionally with 50 μg/ml of ascorbic acid. Cells were treated with or without reagents in regular or serum-deprived conditions (see below), as specified. To induce matrix mineralization, 10 mM β-glycerophosphate (βGP) was added into cultures for 2 days before culture termination. Medium was changed every 2-3 days, and cultures were maintained at 37 °C in a humidified atmosphere with 5% CO 2 .
5-bromo-2'-deoxyuridine (BrdU)-labeling index
Cells at day 7 were serum-deprived (0.1% FCS) for 24 h, and then treated with or without EP agonists or PGE 2 for 24 h, followed by pulse treatment with BrdU (10 μM) for 2 h before culture termination. After fixation in 70% ethanol for 30 min and air drying, cells were permeabilized with 2 M HCl for 5 min. BrdU-labeled cells were detected immunohistochemically by using anti-BrdU monoclonal antibody (1:1,000) and horseradish peroxidase-labeled goat anti-mouse IgG (1:200, Vector Lab) with the avidin-biotin complex (ABC) system (Vector Lab). Each step was followed by two washes (5 min each) with PBS.
Colony formation assay
To obtain colony-forming unit-osteoblasts (CFU-O), cells were plated at very low density (≤200 cells/100-mm dishes) with 10 nM dexamethasone, a potent stimulator of osteoblast development in this model (14) . 
RNA extraction and real-time RT-PCR
Total RNA was isolated from cells with TRIzol reagent (Invitrogen, Carlsbad, CA), according to the manufacturer's directions. cDNA was synthesized from ≤2 μg of total RNA using ReverTra Ace (TOYOBO, Osaka, Japan) at 50 °C for 40 min. Primer sets for rat osteoblast markers and L32 as internal control were described elsewhere [21] ; osteopontin semiquantitative assessment of expression levels, each PCR reaction was realized for different cycles from 16 to 40 cycles, based on points at mid-log phase of the cycles as described elsewhere [22] . PCR products were then size-fractionated on 1% ethidium bromide/agarose gels.
Western blotting
Cells in serum-deprived conditions (0.1% FCS) for a day were treated with reagents as (1:2,000, Santa Cruz Biotechnology) for 1 h, and subjected to chemiluminescent detection (Lumi-Light PLUS , Roche Diagnostics). Each step was followed by three washes (5 min each)
with TTBS. The membranes were then reprobed with corresponding antibodies against non-phosphorylated MAPKs (1:1,000, Santa Cruz Biotechnology).
ALP/von Kossa staining
Cultures were fixed in neutral buffered formalin for 15 min. After washing, cultures were incubated with AS MX-phosphate/blue or red LB in 0.1 M Tris-HCl (pH 8.3). To confirm mineralized nodules, cultures were further treated with 2.5% silver nitrate solution.
Medium PGE 2 measurement
Cells cultured in serum-deprived conditions for a day (day 7) were pretreated in the presence or absence of 1 μM NS-398, an inhibitor of cyclooxyganase (COX)-2 for 3 h and then treated with or without EP agonists or PGE 2 for 4 h. To avoid the interference of the additive reagents, the cells were washed twice with serum-free medium. After an additional incubation for 24 h, the culture medium was collected for PGE 2 measurement
(Prostaglandin E 2 EIA Kit, Cayman Chemical Company, Ann Arbor, MI), according to the manufacturer's protocols.
Intracellular cAMP measurement
Cells at day 7 in serum-deprived conditions (see above) were pretreated with 0.5 μM 3-isobutyl-1-methylxanthine (IBMX) for 20 min, followed by treatment with or without EP agonists, PGE 2 (≤1 μM each) or forskolin (10 μM) for 15 min. After washing with ice-cold PBS, cell lysates were prepared and subjected to cAMP Biotrak Enzymeimmunoassay System (GE Healthcare Biosciences, Little Chalfont, UK), according to the manufacturer's instructions.
Statistical analysis
Data from at least triplicate samples are expressed as the mean ± SD, and two independent experiments were performed at a minimum. Statistical differences were evaluated by analysis of variance (ANOVA) and post hoc Student's t-test.
Results
Both EP2A and EP4A act on nascent nodule-forming cells in RC cell cultures
To assess which EP receptor subtypes are involved in PGE 2 -dependent mineralized nodule formation, we chronically treated with PGE 2 or each of four EP agonists in RC cell cultures.
Similarly to PGE 2 , EP2A and EP4A but not EP1A and EP3A dose-dependently increased the number of mineralized nodules ( Figure 1A -C) and expression of osteoblast marker mRNAs (ALP and OCN) ( Figure 1D ). These effects are comparable to that of rBMP2 as positive control ( Figure 1C ). To determine whether agonist dependency is correlated with corresponding receptor expression, we next asked whether EP receptors are expressed in single cell-derived colonies, CFU-F and CFU-O ( Figure 1E ). RT-PCR showed that EP2 and EP4 mRNAs are expressed not only in CFU-O but also in CFU-F. EP1 mRNA was only faintly detected (at over 40 cycles of PCR) in both colony types, whereas EP3 mRNA was not detected at all.
Previous studies indicated that exposure of either RC or rat bone marrow stromal cells to PGE 2 at relatively early time in culture increases bone nodule formation [23, 24] . To identify more precisely at which developmental stages are the target cells for EP2A and EP4A, we categorized RC cultures into four typical developmental time windows: i.e., proliferating progenitor cells (day 2-5), early differentiating precursor cells associated with nascent nodules (day 5-8), preosteoblasts and immature osteoblasts (day 8-11) and maturing osteoblasts (day 11-14) (Figure 2A) , and pulse-treated with PGE 2 , EP2A or EP4A in the different time windows. PGE 2 and both agonists elicited the largest increase in the number of mineralized nodules formed when cultures were treated at times corresponding to early differentiation-nascent nodule formation stages ( Figure 2B) ; pulse treatment during this window elicited effects as large as chronic exposure to PGE 2 . Concomitantly, we found that PGE 2 , EP2A or EP4A increased BrdU-labeling dominantly in cells associated with nascent nodules (Figure 2C, D) . Furthermore, PGE 2 , EP2A and EP4A all increased the abundance of CFU-ALP ( Figure 2E ). In contrast, treatment with rBMP2 during the developmental time window in which PGE 2 effects were maximal effects (early differentiation-nascent nodule formation) elicited no significant effect on mineralized nodule formation ( Figure 2F ).
To determine whether the developmental time-specific effects of EP2A and EP4A correlate with expression levels of EP receptor subtypes, we compared EP2 and EP4 mRNA levels with osteoblast markers over the developmental sequence; osteoblast markers were ALP, a relatively early marker of osteoblast differentiation; OPN, which peaks during nodule development stages; and BSP and OCN, late markers of osteoblast differentiation ( Figure   3A ). Consistent with the effects elicited by pulse treatment with agonists, both EP2 and EP4 mRNAs were highly expressed at day 7, and were downregulated before BSP and OCN mRNA expression peaked (by day 10). Further, we established the spatial localization of EP2 and EP4 in both RC cell cultures and E21 fetal rat parietal bones by immunofluorescence staining. In day 7 RC cell cultures, EP2 and EP4 were co-localized to Runx2-positive cells in nascent nodules ( Figure 3B ). Immunohistochemistry on E21 fetal parietal bones, the same embryonic day used to isolate RC cells for cultures, demonstrated that EP2 and EP4 were most intensely stained in osteoblasts and their surrounding preosteoblastic cells ( Figure 3C ). Taken together, these results suggest that the expression patterns of EP2 and EP4 receptor subtypes are closely correlated with an apparent site of action of PGE 2 on nodule formation.
EP2A and EP4A elicit overlapping but distinct osteogenic and signaling pathway activities in RC cell cultures and are independent of BMP2
Because both EP2 and EP4 are known to share second messenger signaling [25] , it is not surprising that both agonists show similar effects on the osteoblastic phenotypes in RC cell cultures. However, when we compared the response of cAMP to EP2A and EP4A stimuli in RC cells at day 7, EP2A exhibited a robust effect with dose dependency, in comparison to EP4A or PGE 2 ( Figure 4A ), suggesting that PGE 2 may activate the PKA pathway mostly via EP2 in this model. We further assessed the effect of EP2A and EP4A on the expression of the c-fos protooncogene [26] and cyclin D1 [27] which are upregulated by cAMP-dependent pathways in the mouse osteoblastic MC3T3-E1 and chondrocytic MMA2 cell lines, respectively. Similarly to the effects on cAMP production, EP2A elicited a significant larger effect than EP4A on c-fos and cyclinD1 ( Figure 4B ).
Downregulation of PKA inhibitor G (PKIG) expression in human and mouse stromal cells is
necessary for BMP2-induced osteogenic differentiation [28] , while increased cAMP levels potentiate BMP4-dependent osteo/chondrogenesis in C3H10T1/2, STC2 and MC3T3-E1 cell lines [29] . Thus, although it is unknown how BMP contributes to these processes (at least Smads do not mediate PKIG expression [28] ), the PKA pathway appears to be involved in BMP-dependent osteoblast differentiation. Therefore, we next determined whether EP2A and EP4A differentially regulate BMP2 and BMP4 mRNA expression in RC cells; amongst conditions tested, BMP2 mRNA levels were decreased by both EP2A and EP4A while BMP4 mRNA levels were not changed ( Figure 4C ).
An alternative possibility for the differences seen in some parameters in EP2A-versus EP4A-treated RC cell cultures is that EP2A and EP4A may differentially modulate endogenous production of PGE 2 [30] . We therefore measured PGE 2 production in RC cells at day 7 in the presence or absence of PGE 2 , EP2A or EP4A. All three agonists increased PGE 2 levels in the medium (at least in the absence of NS-398), but there was no significant difference between EP2A and EP4A treatments ( Figure 4D ). The effect of EP2A and EP4A was higher than that of PGE 2 (in the presence of NS-398) ( Figure 4D ). Notably, co-treatment of RC cells with EP2A and EP4A had an additive effect on mineralized nodule formation ( Figure 4E ). Likewise, either a combination of EP2A and rBMP2 or a combination of EP4A and rBMP2 was additive ( Figure 4E ). These results suggest that there may be both common and distinct pathways underlying the EP2 and EP4 actions on mineralized nodule formation and that the signaling pathways elicited by PGE 2 and BMP2
and underlying effects on mineralized nodule formation, while sharing some similarities (e.g., induction of PKA) are not identical.
PGE 2 promotes osteoblastogenesis via summation of its multiple effects on MAPK pathways involved in PKA and PKC signaling in RC cells
Because locally released PGE 2 , acting via PKC-dependent ERK activation, was found recently to be involved in TGF-β-induced proliferation of MC3T3-E1 cells [14] , we assessed whether EP2A and EP4A differentially activate MAPK. When RC cells were treated at day 7, EP2A and EP4A activated predominately p38 MAPK and ERK respectively, and JNK equally ( Figure 5A ). BMP2 activates the p38 MAPK pathway, an effect blocked by Noggin, in the human osteosarcoma MG63 and fetal osteoblastic cell lines [31] , however rNoggin did not inhibit the EP2A-dependent phosphorylation of p38 MAPK in RC cells ( Figure 5B ). To further address whether MAPKs are involved in PGE 2 actions in our model, we pretreated RC cells at day 7 with MAPK inhibitors and assessed the effect of PGE 2 on mineralized nodule formation ( Figure 5C ). Consistent with a report that p38
MAPK plays a positive role in induction of one of the master transcription factors for osteoblast development, osterix, by BMPs in mouse calvaria osteoblastic cells [32] , the p38 MAPK inhibitor SB203580 blocked mineralized nodule formation in the presence or absence of PGE 2 , whereas the JNK inhibitor dicumarol and the ERK inhibitor U0126 only partially blocked the PGE 2 effect. To address further how the MAPK pathway is involved in PGE 2 -dependent osteogenesis, we tested rapid (30 min) responses of RC cells at day 7 to PGE 2 , i.e., transcriptional activation of c-fos and Runx2, the latter another master gene for osteoblastogenesis [33] ( Figure 5D ); similarly to c-fos in MC3T3-E1 cells [26] , Runx2 activation is mediated by a cAMP-dependent pathway in the UMR106-01 rat osteosarcoma cell line [34] . All three inhibitors examined here blocked the induction of Runx2 mRNA by PGE 2 , while c-fos mRNA expression was downregulated only by SB203580. Taken together, these results suggest that each MAPK cascade may be differentially involved in PGE 2 -dependent osteogenic activities in RC cell cultures. To further confirm these cascades, we pretreated RC cells at day 7 with H89 or Go6850 and evaluated the effects of PGE 2 on the phosphorylation of MAPKs ( Figure 5E ). H89 blocked PGE 2 -dependent phosphorylation of p38 MAPK and JNK, while Go6850 inhibited only that of ERK. Similarly, we found that p38 MAPK and ERK were activated by forskolin and PMA, an activator of PKC, respectively ( Figure 5F ). There results suggest that not only PKA but also PKC is involved in PGE 2 -dependent activation of MAPKs in RC cells.
Discussion
We systematically evaluated PGE 2 actions on bone formation and the associated MAPK signaling pathways involved in well-established fetal/newborn RC models by using selective EPAs, which already known . We found, first, that amongst the four EP receptor subtypes, EP2 and EP4 mediate PGE 2 effects on mineralized nodule formation. Second, PGE 2 acts primarily to stimulate proliferation and differentiation of precursor cells associated with newly forming bone nodules. Third, these biological activities were mediated, at least in part, by EP2 (primarily p38 MAPK)-and EP4 (mainly ERK)-dependent MAPK cascades. Finally, these signaling cascades did not entirely overlap with and are distinct from those of BMP2. Taken together, our data suggest that the anabolic effect of PGE 2 on bone formation may be mediated through multiple EP2-and EP4-MAPK signaling pathways.
Early studies exploring EP receptor subtype expression in various osteoblastic cell models (cells from rat calvariae and/or tibiae and MC3T3-E1 cells) [8, 35, 36] gave inconsistent results. All four EPs were subsequently detected in primary osteoblastic cells derived from newborn mouse [9] and fetal rat calvariae [37] . However, because primary cells from calvariae comprise multiple cell types including non-osteoblastic/fibroblastic cells, we further discriminated which cells express which receptor subtype by analyzing single cell-derived colonies, and found no detectable EP3, very low expression of EP1 and robust expression of EP2 and EP4. In keeping with this, EP1A and EP3A had no detectable effects on mineralized nodule formation in our model, suggesting that -although EP1 [24, 37] and EP3 [24] signaling has been measured -PGE 2 response may be mediated mainly through EP2 and EP4 in the RC model. However, given our data on the relative potencies of PGE 2 versus EP2A and/or EP4A on some parameters (for example, see Figure 4A and D), it remains possible that PGE 2 may stimulate not only EP2/EP4 but also EP1, the latter antagonizing the effects of EP2A and/or EP4A.
Growing evidence suggests that not only EP2 but also EP4 is involved in osteoblast development [10-12, 24, 38-41] . However, there are discrepant data on EP2, i.e., data from selective agonists (CP-533,536) in canines [10] and rats [11] vs. PGE 2 treatment of ep2
versus ep4 -/-mice [12] . Direct comparative analyses of either EP2A and EP4A or EP2A and PGE 2 treatment on osteogenic response in fetal rat long bone organ cultures [36] , mouse calvaria cells and/or bone marrow cells [37, 38] have been reported previously. Amongst these reports, the former based on a proline uptake assay in long bones [36] is consistent with our data, but the latter two cell culture reports are discrepant on multiple levels. The basis of the discrepancies is not entirely clear, but it is worth noting that the two earlier cell culture models were analyzed with chronic exposure to NS-398 to inhibit COX-2 activity, and so the answer may lie in differences in endogenous PGE 2 production. It is known that disruption of the cox-2 gene in mice promotes cell proliferation and inhibits mineralized nodule formation in calvaria cell and bone marrow cultures, and PGE 2 rescues mineralized nodule formation in cox-2 -/-bone marrow cultures [42] . Thus, PGE 2 production in osteoblastic cells is necessary for mineralized nodule formation in which the PKA pathway is involved [36] . However, the results from the mouse calvaria cell model treated in the presence of NS-398 indicates that the effects of EP2A on ALP activity and OCN mRNA levels are less than those of EP4A, which is opposite to their activities on cAMP production [26, 36] . Interestingly, the endogenous PGE 2 production elicited by EP2A and EP4A is larger than that by PGE 2 only when the mouse cells were pretreated with NS-398; thus, EP2A and EP4A differentially increase COX-2 transcriptional activity in the presence (EP2A<EP4A) or absence (EP4A>EP2A) of NS-398 in mouse calvaria cells [26] . In our RC model, EP2A and EP4A induce approximately equally PGE 2 production with or without NS-398 co-treatment and both EP2 and EP4 equally and directly contribute to osteoblast development. While additional experiments will be needed to clarify these issues further, the data suggest that EP4 may also mediate mineralized nodule formation independently of the PKA pathway (see below). This view is supported by the fact that, in the RC model, low concentrations (100 nM or less) of selective EP2 and EP4 agonists with high affinity and selectivity [5, 9] were effective, reducing the possibility of crossreactivity amongst EPs.
Second, the RC cell model, as underscored by the quantitative CFU assay, is relatively rich in osteoprogenitor and osteoblastic cells versus other lineages, reducing confounding effects of PGE 2 on non-osteoblastic cells (for example, [43, 44] ). Third, the RC cell model undergoes sequential stages of osteoblast development and bone formation that are well-characterized at the molecular and morphological levels [45] , allowing us to address the stage-specificity of each agonist and dissect out the complex and overlapping multiple effects of PGE 2 . As already raised, both positive and negative effects of PGE 2 on proliferation/differentiation have been described in different osteoblastic cell models [46] but only a few studies have been directed at trying to separate effects of PGE 2 on more or less differentiated osteoblast precursors. For example, formation of mineralized nodules was increased when post-confluent RC cell cultures were treated with PGE 2 [23] . CFU characterized by slowly proliferating ALP-negative cells were increased in limiting dilution analysis of PGE 2 -treated RC cells [47] . Our data indicate that at least one major target cell of PGE 2 is the osteogenic precursor that can further proliferate and differentiate [45] .
The molecular mechanisms underlying PGE 2 effects have been elucidated in several cell types including cancer cells [18] . However, until recently, the signaling pathway(s) by which PGE 2 directly influences osteoblast development has remained elusive. Although almost all parameters measured here showed that the efficacy of EP2A was similar or a little higher than that of EP4A, the EP2 receptor elicited much more cAMP production than EP4, as discussed above (see also [30] ). Because EP2A and EP4A show similar physicochemical properties [5, 9] , one possibility is that the differences in efficacy may be attributable to differences in EP2 and EP4 receptor expression, such as relative level and distribution [48, 49] . Additionally, our data strengthen the linkage of PGE 2 to MAPKs as recently described in MC3T3-E1 cells [14] . Insulin-like growth factor-I-mediated osterix expression in human mesenchymal stem cells required all three MAPK pathways (p38 MAPK, JNK and ERK) and PKD signaling, whereas BMP2 requires p38 MAPK during osteoblast linage progression [50] . BMP [51, 52] , PKC [53] , and PKA [54] suggest that the JNK pathway negatively regulates cell proliferation in osteoblasts as it does in liver myofibroblasts [55] . Our data with PKA/PKC activators/inhibitors also suggest that EP4 may activate the PKC pathway which contributes to ERK activation in RC cells, as it does in HEK-293 EBNA cells expressing EP4 [16] . Taken together, our results support the important conclusion that the activation of MAPKs by PGE 2 may be differentially regulated in a receptor subtype-dependent manner, which is the first evidence for a difference in EP2-and EP4-dependent signaling in osteoblasts.
In summary, we systematically characterized PGE 2 actions on bone formation in the RC cell model. EP2 acts principally through the cAMP-p38 MAPK-c-fos/Runx2 pathway, while EP4 may also stimulate ERK, possibly via PKC, and is involved in Runx2 expression. JNK appears to be activated equally by both EP2 and EP4, which may also contribute to regulation of Runx2 expression. These MAPK pathways mediate the osteoblastogenic activities of PGE 2 , with a resultant increase in bone formation. analysis of c-fos and Runx2. Cells at day 7 were pretreated with the MAPK inhibitors (10 μM each) for 3 h, followed by treatment with 100 nM PGE 2 for 30 min under serum-derived conditions. (E) Cells at day 7 were pretreated with or without 10 μM H89 or 1 μM Go6850 (Go) for 1 h, followed by treatment with 100 nM PGE 2 for 5 min under serum-deprived conditions. (F) Cells at day 7 were treated with 10 μM forskolin (FSK) or 1 μM PMA for 5 min. Western blot analysis was performed to determine activation of
